In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the ...

Three decades ago, a scientist at the University of Texas named Bruce Beutler asked the U.S. government to grant him a patent for a new invention. Beutler, who would later win the Nobel Prize for his ...

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster ...

Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader Ugur Sahin prepares to join a fledgling mRNA startup.

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims ...

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...

The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public ...

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its ...

Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for ...

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy ...

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two ...